BW Gestao de Investimentos Ltda. disclosed a substantial buy in UiPath on its November 13, 2025, SEC filing, increasing its stake by $35.69 million quarter-over-quarter. This was a buy, lifting UiPath ...

The AI orchestration platform is seeing its revenue accelerate. However, the company is just starting to tap into its potential. Meanwhile, the stock is still cheap despite its recent surge. For those ...

While tech companies have been eager to see what generative AI can do, we're in the early days of adoption - and according to Dr Ed Challis, Head of AI Strategy at UiPath, there is still a significant ...

So I wrote an epic missive on the absurdity of AI agent overhype, hopped on a plane to Vegas, to hear UiPath make splashy news announcements about... AI agents. How did that go over with me? A bit ...

UiPath remains a buy, outperforming the S&P 500 with a 53.6% gain since March 2025, driven by operational turnaround. PATH's revenue growth re-accelerated to 15.9% in Q3 FY26, with raised full-year ...

UiPath's stock has dropped ~20% since January, presenting a buying opportunity for long-term investors, despite macroeconomic concerns and disappointing Q4 results. UiPath focuses on agentic ...

Valued at $6.4 billion by market cap, UiPath is an enterprise-facing automation platform that offers a range of RPA (robotic process automation) solutions to clients in verticals such as banking, ...

UiPath's software helps companies automate processes and manage artificial intelligence (AI) agents. The enterprise agentic AI market is projected to grow at a high rate and could be a huge ...

Omega Healthcare partnered with UiPath to automate medical billing and other administrative tasks. The revenue cycle management company has saved employees hours with its AI document-processing tool.